

CITATION REPORT

List of articles citing

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

DOI: 10.1007/s10549-020-05577-7

Breast Cancer Research and Treatment, 2020, 180, 597-609.

Source: <https://exaly.com/paper-pdf/77240926/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer. <i>Cancer Biology and Medicine</i> , 2020 , 17, 1014-1025	5.2	3
19	The role of ado-trastuzumab emtansine in current clinical practice. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 150-155	1.7	2
18	Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). <i>Breast Cancer</i> , 2021 , 28, 581-591 ^{3,4}	3.4	4
17	Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis. <i>Journal of Cancer</i> , 2021 , 12, 1687-1697	4.5	0
16	Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. <i>Neuro-Oncology</i> , 2021 , 23, 1656-1667	1	1
15	Invasive ductal breast carcinoma preceded by CALR-positive essential thrombocythemia. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, 1732-1736	0.7	
14	Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China. <i>Clinical Drug Investigation</i> , 2021 , 41, 569-577	3.2	0
13	Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 608781	5.3	0
12	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021 , 48, 246-258	5.5	1
11	Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. <i>Future Oncology</i> , 2021 , 17, 4635-4647	3.6	2
10	Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer: Single-center Preliminary Results. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 895-901	2.7	7
9	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2020 , 8, 1634	3.2	1
8	Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study. <i>American Journal of Translational Research (discontinued)</i> , 2021 , 13, 10863-10870	3	
7	Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. <i>Journal of Investigative Medicine</i> , jim-2021-002298	2.9	2
6	Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 177, 103758	7	
5	Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups. 12,		
4	The Evaluation of Clinical Status of Endoscopic Retrograde Cholangiography for the Placement of Metal and Plastic Stents in Cholangiocarcinoma Therapy. 2022 , 2022, 1-8		0

- 3 Quantitative chemometric phenotyping of three-dimensional liver organoids by Raman spectral imaging. **2023**, 100440 ○
- 2 Model-based assessment of combination therapies ranking of radiosensitizing agents in oncology. **2023**, 23, ○
- 1 Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy. ○